BioBridge Symposium held at 30th World Congress of the International Society of Lymphology (ISL)

Oct 16, 2025

Fibralign Corp. and leading physicians presented an update on clinical findings and case studies during the 30th World Congress of the International Society of Lymphology (ISL), which was held 15-19 October 2025 in Antalya, Turkey. As part of this session, Dr. Corrado Campisi, incoming President of ISL, presented his prospective randomized clinical study (n=34) using BioBridge with advanced microsurgery procedures.

This was the second time that ISL hosted a BioBridge-focused session during their bi-annual congress meeting, with the previous session held in Genoa, Italy in September, 2023.

 

Fibralign Selected as a UCSF Rosenman Institute Innovator

Fibralign Selected as a UCSF Rosenman Institute Innovator

Jun 10, 2021

NCI-funded study evaluating Fibralign’s BioBridge® as an adjunct to microsurgical treatment SAN FRANCISCO, June 10, 2021 /PRNewswire/ -- The UCSF Rosenman Institute is proud to announce the 2021 cohort of the Rosenman Innovators, a group of early-stage health...

read more
Fibralign Announces CE Mark Approval for BioBridge®

Fibralign Announces CE Mark Approval for BioBridge®

Sep 14, 2020

European approval for novel device supporting surgical treatment of lymphedema September 14, 2020 (Union City, CA) – Fibralign Corp., a Stanford spin-out and developer of therapeutic biomedical devices, today announced that it has received CE mark for its first...

read more